Table 9.

Dose modification according to organ dysfunction and metabolism are listed. Half life is measured in hours for all drugs except vandetanib and vismodegib (days).

	Child-Pugh Classification			Renal Impairment			Single Dose Half Life (hours)	Hepatic Excretion	Renal Excretion
Kinase Inhibitor	A	B	C	Mild	Moderate	Severe (not including HD)
Axitinib	No adjustment	reduce dose		No adjustment	No adjustment	No adjustment	2.5-6	41%	23%
Bosutinib	200 mg	200 mg	200 mg	No adjustment	No adjustment	Do not use	22.5	91.3%	3%
Cabozantinib		Do not use	Do not use	No adjustment	No adjustment		55	54%	27%
Crizotinib				No adjustment	No adjustment		42	63%	22%
Dasatinib	No adjustment	No adjustment	No adjustment				3∼5	85%	4%
Erlotinib	No adjustment	No adjustment	Use caution				36.2	83%	8%
Gefitinib	No adjustment	No adjustment	No adjustment	No adjustment	No adjustment		48	86%	4%
Imatinib	No adjustment	No adjustment	Decrease dose by 25%	≤600 mg	≤ 400 mg; reduce by 50%	100 mg	17.1	68%	13%
Lapatinib	No adjustment	No adjustment	Reduce dose				14	Most	<2%
Nilotinib	Reduce dose	Reduce dose	Reduce dose	No adjustment			17(Multi-day dosing)	93%
Pazopanib	No adjustment	Reduce to 200mg	Do not use	No adjustment	No adjustment		30.9	Most	<4%
Regorafenib	No adjustment	No adjustment	Do not use	No adjustment	Do not use	Do not use	28	71%	19%
Ruxolitinib	Reduce dose	Reduce dose	Reduce dose	No adjustment	Reduce dose	Reduce dose	3	22%	74%
Sorafenib	No adjustment	No adjustment		No adjustment	No adjustment	No adjustment	25-48	77%	19%
Sunitinib	No adjustment	No adjustment		No adjustment	No adjustment	No adjustment	40-60	61%	16%
Vandetanib		Do not use	Do not use	No adjustment	200 mg	200 mg	19 days	44%	25%
Vemurafenib	No adjustment	No adjustment		No adjustment	No adjustment		57	94%	1%
Vismodegib							12 days	82%	4.4%
Ponatinib	Not studied	avoid	avoid	Not studied	avoid	avoid	24	87%	5%

Abbreviations: HD, hemodialysis.